Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06418594
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-05-13
Brief Title:
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Sponsor:
Beijing 302 Hospital
Organization:
Beijing 302 Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-13
First Submit QC Date:
May 15 2024
Study First Post Date:
2024-05-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-15
Last Update Post Date:
2024-05-17
Last Update Post Date Type:
ACTUAL